Foldrx Pharms Drug Patent Portfolio

Foldrx Pharms owns 2 orange book drugs protected by 5 US patents Given below is the list of Foldrx Pharms's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9770441 Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole 31 Aug, 2035
Active
US7214695 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding 19 Dec, 2025
Active
US7214696 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding 19 Dec, 2025
Active
US8168663 Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof 19 Dec, 2023 Expired
US8653119 Methods for treating transthyretin amyloid diseases 19 Dec, 2023 Expired


Given below is the list of recent legal activities going on the following drug patents of Foldrx Pharms.

Activity Date Patent Number
Patent litigations
Second letter to regulating agency to determine regulatory review period 29 Apr, 2024 US7214696
Second letter to regulating agency to determine regulatory review period 29 Apr, 2024 US7214696
Second letter to regulating agency to determine regulatory review period 29 Apr, 2024 US7214695
Second letter to regulating agency to determine regulatory review period 29 Apr, 2024 US7214695
Letter from FDA or Dept of Agriculture re PTE application 08 Feb, 2024 US7214695
Letter from FDA or Dept of Agriculture re PTE application 08 Feb, 2024 US7214695
Letter from FDA or Dept of Agriculture re PTE application 08 Feb, 2024 US7214696
Letter from FDA or Dept of Agriculture re PTE application 08 Feb, 2024 US7214696
Payment of Maintenance Fee, 12th Year, Large Entity 18 Oct, 2023 US8168663
Interim Patent Term Extension Granted 13 Oct, 2023 US7214695
Interim Patent Term Extension Granted 13 Oct, 2023 US7214695
Interim Patent Term Extension Granted 13 Oct, 2023 US7214696
Interim Patent Term Extension Granted 13 Oct, 2023 US7214696
Change in Power of Attorney (May Include Associate POA) 23 Aug, 2023 US8168663
Email Notification 23 Aug, 2023 US8168663


Foldrx Pharms's Family Patents

Foldrx Pharms drugs have patent protection in a total of 18 countries. It's US patent count contributes only to 23.1% of its total global patent coverage. Click below to unlock the full patent family tree.

Family Patents



Foldrx Pharms Drug List

Given below is the complete list of Foldrx Pharms's drugs and the patents protecting them.


1. Vyndamax

Vyndamax is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9770441 Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole 31 Aug, 2035
(10 years from now)
Active
US7214695 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding 19 Dec, 2025
(1 year, 27 days from now)
Active
US7214696 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding 19 Dec, 2025
(1 year, 27 days from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vyndamax's drug page


2. Vyndaqel

Vyndaqel is protected by 4 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7214695 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding 19 Dec, 2025
(1 year, 27 days from now)
Active
US7214696 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding 19 Dec, 2025
(1 year, 27 days from now)
Active
US8168663 Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof 19 Dec, 2023
(11 months ago)
Expired
US8653119 Methods for treating transthyretin amyloid diseases 19 Dec, 2023
(11 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vyndaqel's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List